Trial Profile

Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, and Severe Juvenile Dermatomyositis

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Nov 2021 Results (n=10) assessing disease flares in CANDLE/PRAAS with dose reductions of baricitinib, presented at the ACR Convergence 2021
09 Nov 2021 Results (n=4) assessing Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis presented at the ACR Convergence 2021
14 Nov 2017 Results of pooled data from two trial (NCT02974595 and NCT01724580) assessing pharmacokinetics, pharmacodynamics and oral dosing regimen of baricitinib in patients with rare interferonopathies, were published in the Clinical Pharmacology and Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com